* Benitec Biopharma Inc is expected to show a fall in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Benitec Biopharma Inc is for a loss of 78 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Benitec Biopharma Inc is $16.00, above its last closing price of $9.18.
This summary was machine generated May 10 at 12:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments